Understanding the many roads that can lead to amyotrophic lateral sclerosis (ALS)is a painstaking but necessary prerequisite to development of disease-modifying treatments. Recently, several research teams have made contributions to this effort. A 2011 MDA career development grant to Adrian Israelson, who was then at the University of California, San Diego, was crucial to the finding that the MIF protein counteracts the effects of ALS-causing mutations in the SOD1 gene.
Biopharmaceutical company Genervon has announced what it considers encouraging results from a "compassionate use" trial of its experimental drug GM604 in a single patient with advanced amyotrophic lateral sclerosis (ALS).
Stem cells -- cells at an early stage of development that can mature and fulfill specific roles depending on their environment and signals they receive – have intrigued scientists as a possible treatment for amyotrophic lateral sclerosis (ALS) for several years. Now, two biotechnology companies – BrainStorm Cell Therapeutics and Neuralstem – are reporting encouraging results from ALS clinical trials.